API | IPH2101

IPH2101 Report issue

Biologics mAb Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

1-7f9

iph-2101

More Chemistry

Pharmacology

Mechanisms of Action:
- Killer cell immunoglobulin-like receptor 2DL1 (Homo sapiens) ^UniProt
- Killer cell immunoglobulin-like receptor 2DL2 (Homo sapiens) ^UniProt
- Killer cell immunoglobulin-like receptor 2DL3 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1-7f9 | 1-7f9 monoclonal antibody | anti-kir | anti-kir (1-7f9) | ch-mab7f9 | iph2101 | iph 2101 | iph-2101 | nn1975 | nn 1975 | nn-1975

Organizations (13)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Leukemia, Myeloid, Acute (Phase 1)

Methamphetamine (Phase 1)

Multiple Myeloma (Phase 2)

Smoldering Multiple Myeloma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue